- Home
- ACIU vs DBI Comparison
ACIU vs DBI Comparison
Compare ACIU & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- DBI
- Stock Information
- Founded
- ACIU 2003
- DBI 1991
- Country
- ACIU Switzerland
- DBI United States
- Employees
- ACIU N/A
- DBI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- ACIU Health Care
- DBI Consumer Discretionary
- Exchange
- ACIU Nasdaq
- DBI Nasdaq
- Market Cap
- ACIU 247.4M
- DBI 222.4M
- IPO Year
- ACIU 2016
- DBI 1991
- Fundamental
- Price
- ACIU $1.77
- DBI $2.99
- Analyst Decision
- ACIU Strong Buy
- DBI Hold
- Analyst Count
- ACIU 2
- DBI 2
- Target Price
- ACIU $12.00
- DBI $4.75
- AVG Volume (30 Days)
- ACIU 185.3K
- DBI 1.8M
- Earning Date
- ACIU 05-12-2025
- DBI 03-20-2025
- Dividend Yield
- ACIU N/A
- DBI 6.69%
- EPS Growth
- ACIU N/A
- DBI N/A
- EPS
- ACIU N/A
- DBI N/A
- Revenue
- ACIU $30,136,397.00
- DBI $3,009,262,000.00
- Revenue This Year
- ACIU N/A
- DBI $3.51
- Revenue Next Year
- ACIU $680.74
- DBI $2.60
- P/E Ratio
- ACIU N/A
- DBI N/A
- Revenue Growth
- ACIU 84.51
- DBI N/A
- 52 Week Low
- ACIU $1.77
- DBI $2.87
- 52 Week High
- ACIU $4.98
- DBI $11.06
- Technical
- Relative Strength Index (RSI)
- ACIU 25.49
- DBI 33.36
- Support Level
- ACIU $1.77
- DBI $3.71
- Resistance Level
- ACIU $2.05
- DBI $3.99
- Average True Range (ATR)
- ACIU 0.12
- DBI 0.34
- MACD
- ACIU -0.02
- DBI -0.01
- Stochastic Oscillator
- ACIU 0.00
- DBI 7.72
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.